Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed Leishmania donovani Antigen Immunomodulatory System in Visceral Leishmaniasis
ACS Applied Bio Materials · 2026
DOI: 10.1021/acsabm.5c02526 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Bio Materials, 2026. Verfasst von Sandeep Kaur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology Lab, Department of Zoology, Panjab University, Chandigarh 160014, India. Hauptthemen laut MEDLINE: Leishmania donovani, Leishmaniasis, Visceral, Toll-Like Receptor 7, Toll-Like Receptor 8. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Visceral leishmaniasis (VL) is a fatal parasitic disease for which safe and effective immunotherapeutic strategies remain limited. Modulation of innate immune signaling using small-molecule Toll-like receptor (TLR) agonists represents a promising approach to enhance host-directed antiparasitic responses. In this study, we investigated the immunomodulatory efficacy of a synthetic TLR7/8 agonist, HYBRID2, formulated with formalin-killed Leishmania donovani antigen (FK), in a BALB/c mouse model of VL. Immunized mice challenged with L. donovani exhibited a marked reduction in splenic parasite burden following FK + HYBRID2 administration. Mechanistic evaluation of splenocytes revealed enhanced redox activity, with significantly elevated reactive oxygen species and nitric oxide production, accompanied by up-regulation of inducible nitric oxide synthase and NF-κB expression. Cytokine analysis demonstrated a pronounced Th1-biased immune response, characterized by increased INF-γ and TNF-α levels. Comparative assessment showed that FK + HYBRID2 elicited superior immunostimulatory and antileishmanial effects relative to FKAlone or FK combined with Resiquimod. Collectively, these findings establish HYBRID2 as a potent innate immune modulator enhancing redox responses and NF-κB activation alongside Th1 polarization, highlighting its potential utility as an immunomodulatory adjuvant platform against intracellular parasitic infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parasitology Lab, Department of Zoology, Panjab University, Chandigarh 160014, India.
- Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh 160014, India.
- National Interdisciplinary Centre of Vaccine, Immunotherapeutics and Antimicrobials (NICOVIA), Panjab University, Chandigarh 160014, India.
- Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research, Sector 67, S. A. S., Nagar, Punjab 160062, India.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Kaur, S., Thakur, S., Kumar, K., Kaur, S., & Salunke, D. B. (2026). Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed Leishmania donovani Antigen Immunomodulatory System in Visceral Leishmaniasis. ACS Applied Bio Materials. https://doi.org/10.1021/acsabm.5c02526
Vancouver
Kaur S, Thakur S, Kumar K, Kaur S, Salunke DB. Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed Leishmania donovani Antigen Immunomodulatory System in Visceral Leishmaniasis. ACS Applied Bio Materials. 2026. doi:10.1021/acsabm.5c02526
BibTeX
@article{Kaur2026,
author = {Kaur, Sandeep and Thakur, Shivani and Kumar, Kushvinder and Kaur, Sukhbir and Salunke, Deepak B},
title = {Tuning Th1 Immunity through a TLR7/8 Agonist HYBRID2-Formalin-Killed Leishmania donovani Antigen Immunomodulatory System in Visceral Leishmaniasis},
journal = {ACS Applied Bio Materials},
year = {2026},
doi = {10.1021/acsabm.5c02526}
}
EUVIMED